Abstract: Disclosed herein are novel compositions and methods for the treatment of inflammation. Also described herein are methods for the identification of agents useful in the foregoing methods. The invention relates to methods for treatment and prevention of disorders associated with inflammation by administering agents that may also increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

Abstract: The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an “NMN-like” moiety linked to another moiety with biological activity upon administration. In some cases, the disease to be treated is infection with viruses. Such viruses include coronaviruses, such as SARS, MERS, or COVID-19, HIV, and viruses associated with hepatitis. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD) in cells and tissues for treating diseases and/or improving cell and tissue survival.

Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

Abstract: The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical compositions containing one or more NAD+ modulating compounds as a first ingredient in combination with one or more active pharmaceutical ingredients. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and/or improving cell and tissue survival.

Abstract: The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an “NMN-like” moiety linked to another moiety with biological activity upon administration. In some cases, the disease to be treated is infection with viruses. Such viruses include coronaviruses, such as SARS, MERS, or COVID-19, HIV, and viruses associated with hepatitis. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD) in cells and tissues for treating diseases and/or improving cell and tissue survival.

Abstract: The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an “NMN-like” moiety linked to another moiety with biological activity upon administration. In some cases, the disease to be treated is infection with viruses. Such viruses include coronaviruses, such as SARS, MERS, or COVID-19, HIV, and viruses associated with hepatitis. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD) in cells and tissues for treating diseases and/or improving cell and tissue survival.

Abstract: The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies.

Abstract: The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies.